etesevimab injection、Etesilmab injection 埃特司韦单抗注射液

Etesilmab (JS016) is a fully human monoclonal neutralizing antibody drug for the treatment of COVID-19 jointly developed by the Institute of Microbiology, Chinese Academy of Sciences and Shanghai Junshi Biopharma Co., Ltd. The drug binds to the receptor binding domain of the coronavirus spike protein, blocking the binding of the virus to the human cell receptor ACE2, thereby preventing the virus from invading cells [1-2]. In a Phase III clinical trial, the dual antibody combination therapy with barniviromab showed that it could reduce the risk of hospitalization and death in mild and moderate high-risk patients by 70%-84%, and the protection rate for death cases was 100%. As of December 2021, the therapy has been granted emergency use authorization in 15 countries and regions including the United States and the European Union, with a cumulative use of more than 500,000 doses worldwide [1] [3-4]. In September 2021, the U.S. Food and Drug Administration (FDA) further approved its use for post-exposure prophylaxis in specific high-risk populations.